Introducing the 9th Annual RNA Therapeutics 2018
One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and evaluate with key industry leaders the lessons they’ve learnt whilst developing an RNA therapeutic.
Join us in February 2018, as SMi’s RNA Therapeutics Conference brings together industry experts from leading RNA companies to analyze and evaluate the latest advancements, including SaRNA as a potential therapeutic for people with liver cancer, advances in targeted delivery of nucleotides beyond the liver and the latest developments in delivery systems, such as exosomes and nanocomplexes.
Network and learn from leading professionals such as:
- Nagy Habib, Head of HPB Surgery, Imperial College London and Co-Founder, MiNA Therapeutics
- Shalini Andersson, Senior Director Drug Metabolism & Pharmacokinetics, AstraZeneca R&D
- Ekkehard Leberer, Senior Director, Sanofi
- Jeffrey Ulmer, Head Preclinical R&D, GSK
- James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals
- Mariola Fotin-Mleczek, Chief Scientific Officer, CureVac
- Bob D. Brown, Chief Scientific Officer and Senior Vice President, Research, Dicerna Pharmaceuticals
- Oliver Rausch, VP Research & Development, Storm Therapeutics
- Kirsty Wydenbach, Senior Medical Assessor, Deputy Unit Manager, Clinical Trials Unit, MHRA
Some Featured Highlights will include:
- Hear from MiNA Therapeutics about their new pre-clinical data supporting the on-target mechanism of action of their pioneering new drug candidate MTL-CEBPA.
- Learn how CureVac’s sophisticated technologies and approaches have helped overcome limitations such as the instability of single-stranded RNA.
- Discover STORM Therapeutics’ innovative approach: Harnessing the power of RNA epigenetics to develop first-inclass drugs in oncology.
- Expand your knowledge of patenting RNA Therapeutics, with James Ogle, a European and UK Chartered Patent Attorney with particular expertise in RNA and other nucleic acid based technologies.
- Examine the latest developments in delivery systems for RNA Therapeutics, including Exosomes, Nanocomplexes and Platform Delivery Approaches.
For those looking to attend there is currently a £400 early-bird saving, ending October 31st
Further information is available at: www.therapeutics-rna.com/opr
SMi presents the 9th Annual Conference:
Date: 21st – 22nd February 2018
Location: Holiday Inn London - Kensington Forum
For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: firstname.lastname@example.org
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
1 Westminster Bridge Rd, London SE1 7XW
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Introducing the 9th Annual RNA Therapeutics 2018 here
News-ID: 766240 • Views: 1030
More Releases from SMi Group
Darren Green, GSK, conference chair invitation to attend 3rd Annual AI in Drug D …
SMi Reports: Conference Chairman Darren Green from GSK personally invites you the 3rd Annual AI in Drug Discovery Conference taking place on 14th and 15th March 2022 in London, UK. The conference will have a focus on case studies from leading pharma and biotech firms, as well as a exploring the latest innovations in machine learning for enhancing discovery pipelines. Darren Green, Director of Computational Chemistry at GSK will be chairing at
Registration is open for SMi’s 5th Annual Pharmaceutical Microbiology East Coa …
SMi Group reports: The 5th Annual Pharmaceutical Microbiology East Coast Conference is set to return in April 2022 with a key focus existing methods and novel tools in microbial control to assure continuity in product quality and patient safety. SMi Group is delighted to announce the 5th Annual Pharmaceutical Microbiology East Coast Conference, taking place on the 27th and 28th April 2022 in Boston, USA. The 2022 Conference theme is
SMi’s 10th Annual Pharmaceutical Microbiology UK Conference - A Virtual Confer …
SMi Reports: SMi Group have made the decision to open the microbiology conference and workshops to all microbiologists by transforming it into a virtual-remote online access event only on 17th and 18th January 2022. SMi’s 10th Annual Pharmaceutical Microbiology UK Conference will no longer take place in London, UK. Instead, the conference is taking place on 17 and 18 January 2022 and will open its doors to a global audience delivering
Co-chairs Philip Hewitt and Stefan Pryzyborski, invitation to join SMi’s 5th A …
SMi Group reports: Co-Chairs, Philip Hewitt and Stefan Pryzyborski for SMi’s 5th Annual 3D Cell Culture invite industry professionals to join the conference in February 2022. Philip Hewitt, Global Head of Early Investigative Toxicology, Merck and Stefan Przyborski, Professor in Cell Technology, Durham University invite industry professionals by releasing invite letter to join SMi’s 5th Annual 3D Cell Culture Conference 2022. This event will convene on February 9th – 10th 2022,
More Releases for RNA
Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand. Browse 156 Market Data Tables and 112 Figures spread through 175
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited. Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led
Special student rate for RNA Nanotechnology conference
Fusion Conferences and the Chairs of RNA Nanotechnology have introduced a Special Student Rate for their conference on 01-04 August 2016. The conference, to be held at Wokefield Park in Berkshire, UK, sold out earlier this month with registrations being closed off to the public, but Fusion have opened up some spaces to allow students to enjoy the conference at a discounted rate. Dr. Peixuan Guo of Ohio State University and one